Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2017

View Archived Issues

Juno Therapeutics enters various agreements for multiple myeloma program

FDA expands orphan drug designation for patisiran

FDA grants orphan drug designation to PLX-100 for the treatment of neuronal ceroid lipofuscinoses

Janssen submits sNDA in U.S. for two new Xarelto indications

CRISPR Therapeutics applies to conduct clinical trial of CTX-001

Semi-synthetic organism encodes and retrieves increased genetic information

HMBD-004, a bispecific antibody targeting CD47 and CD33, shows promise for AML

Phase III IMmotion151 trial meets co-primary endpoints

FDA accepts BLA for galcanezumab for prevention of migraine

FDA accepts sBLA for Keytruda, grants priority review

BioVie's BIV-201 given FDA fast track designation

Topline results reported from phase II study of ARGX-113 in myasthenia gravis

Harpoon Therapeutics patents CD3-binding antibodies

Rockefeller University presents novel FXIIa inhibitors

University of California identifies new growth factors for bone regeneration

Aelin Therapeutics secures series A financing

Roche exercises option to license IONIS-HTTrx

Novel PD-1 signaling inhibitors presented by Incyte

Mereo BioPharma reports phase II results for acumapimod in COPD

FDA approves Sanofi's follow-on insulin product

Favorable initial results seen with INCB-057643 in patients with advanced cancer

PsiOxus receives milestone payment upon CTA approval for NG-348

Altimmune submits IND application for anthrax vaccine

Allergan to acquire Repros Therapeutics

Proteostasis reports data across three cystic fibrosis programs

Neurotransmitter alterations identified in novel model of ictogenesis

NIH supports new Alzheimer's Clinical Trial Consortium

NeuroVive reports interim results from phase I study of KL-1333

Almirall and Athenex to collaborate on developing KX2-391

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...